Published in the Nov-Dec 2018 issue of MedNous,
a publication of Evernow Publishing Ltd.
This year, the annual conference of the European Society of Gene and Cell Therapy carried the subtitle ‘changing the face of modern medicine.’ This was a reference to not just new therapies, but also to the latest dug production technologies. While Pharma and biotech companies aim to develop novel therapies eliminating the underlying cause of a disease and thereby healing the patient instead of just targeting the symptoms, technology companies explore innovative production systems to provide enough material to bring these modern medicines through the clinic and to commercialisation.
Scalable, helper virus-free AAV production with stable CAP-GT producer cell lines
Free Accessible Webinar with Dr. Nicole Faust – Cell & Gene Therapy Insights – November 2018
Current production methods for viral vectors tend to use adherently growing cells and transient transfection, a manual process which allows only for scale-out and not for scale-up. Upscaling GMP production of viral vectors is currently one of the big technical challenges in gene therapy manufacture. CEVEC has developed the fully scalable CAP-GT platform, based on serum-free suspension cells which can efficiently produce lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) vectors at industrial scale.
Watch this Free On Demand webinar with Dr Nicole Faust, CEO & CSO of CEVEC Pharmaceuticals GmbH, to gain insight on the newly developed AAV packaging system, allowing the helper virus-free stable production of AAV vectors without the need of a transient transfection step